

Drug Monograph

Drug Name: **Kloxxado™ (naloxone) nasal spray**
 Drug Class: **Central Nervous System: Analgesics, Opiate Emergency Reversal Agents**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Kloxxado is available as a nasal spray containing 8 mg/0.1 ml.

Manufacturer: Distributed by: Hikma Specialty USA Inc., Columbus, OH 43228.

Indications: Kloxxado is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.

Costs: \$125 per 2-sprayer pack Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL). The MO Healthnet Division also recommends adding this drug to the current High Risk Therapy clinical edit.

Status Recommendation:	<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PA Required
	<input type="checkbox"/> Open Access	<input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non-Preferred
	<input type="checkbox"/> No PA Required	<input checked="" type="checkbox"/> Preferred

Prepared by: April Ash, PharmD.
 Date: September 1, 2021